The use of sulfonylurea hypoglycemic agents, while widely prescribed in DM2 patients for baseline glycemic control, may be contraindicated in clinical setting post cerebral ischemia because their mechanism of action, the inhibition of pancreatic beta-cell KATP channels to augment insulin secretion, may concurrently interfere with cerebral ischemic protection by a mechanism that requires neuronal KATP channel activation [38]. Here, INS is linked to Cerebral ischemia.